These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2238051)

  • 1. Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantation.
    Cooper MM; Robbins RC; Goldman CK; Mirzadeh S; Brechbiel MW; Stone CD; Gansow OA; Clark RE; Waldmann TA
    Transplantation; 1990 Nov; 50(5):760-5. PubMed ID: 2238051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolongation of graft survival in primate allograft transplantation by yttrium-90-labeled anti-Tac in conjunction with granulocyte colony-stimulating factor.
    Parenteau GL; Dirbas FM; Garmestani K; Brechbiel MW; Bukowski MA; Goldman CK; Clark R; Gansow OA; Waldmann TA
    Transplantation; 1992 Dec; 54(6):963-8. PubMed ID: 1281566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival.
    Brown PS; Parenteau GL; Dirbas FM; Garsia RJ; Goldman CK; Bukowski MA; Junghans RP; Queen C; Hakimi J; Benjamin WR
    Proc Natl Acad Sci U S A; 1991 Apr; 88(7):2663-7. PubMed ID: 2011577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humanized antibody directed to the IL-2 receptor beta-chain prolongs primate cardiac allograft survival.
    Tinubu SA; Hakimi J; Kondas JA; Bailon P; Familletti PC; Spence C; Crittenden MD; Parenteau GL; Dirbas FM; Tsudo M
    J Immunol; 1994 Nov; 153(9):4330-8. PubMed ID: 7930631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody.
    Reed MH; Shapiro ME; Strom TB; Milford EL; Carpenter CB; Weinberg DS; Reimann KA; Letvin NL; Waldmann TA; Kirkman RL
    Transplantation; 1989 Jan; 47(1):55-9. PubMed ID: 2643232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac.
    Waldmann TA; White JD; Carrasquillo JA; Reynolds JC; Paik CH; Gansow OA; Brechbiel MW; Jaffe ES; Fleisher TA; Goldman CK; Top LE; Bamford R; Zaknoen E; Roessler E; Kasten-Sportes C; England R; Litou H; Johnson JA; Jackson-White T; Manns A; Hanchard B; Junghans RP; Nelson DL
    Blood; 1995 Dec; 86(11):4063-75. PubMed ID: 7492762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-IL-2 receptor monoclonal antibody (anti-Tac) treatment of T-cell lymphoma.
    Waldmann TA
    Important Adv Oncol; 1994; ():131-41. PubMed ID: 8206486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation.
    Kirkman RL; Shapiro ME; Carpenter CB; McKay DB; Milford EL; Ramos EL; Tilney NL; Waldmann TA; Zimmerman CE; Strom TB
    Transplantation; 1991 Jan; 51(1):107-13. PubMed ID: 1846250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts.
    Waldmann TA; Goldman CK
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):45-53. PubMed ID: 2683757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment with cyclosporine and anti-interleukin 2 receptor antibody abrogates the anti-idiotype response in rat recipients of cardiac allografts.
    Tanaka K; Tilney NL; Stunkel KG; Hancock WW; Diamantstein T; Kupiec-Weglinski JW
    Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7375-9. PubMed ID: 2217171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective immunosuppression with anti-interleukin 2 receptor-targeted therapy: helper and suppressor cell activity in rat recipients of cardiac allografts.
    Kupiec-Weglinski JW; Padberg W; Uhteg LC; Ma L; Lord RH; Araneda D; Strom TB; Diamantstein T; Tilney NL
    Eur J Immunol; 1987 Mar; 17(3):313-9. PubMed ID: 2952511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The xenoantibody response and immunoglobulin gene expression profile of cynomolgus monkeys transplanted with hDAF-transgenic porcine hearts.
    Zahorsky-Reeves JL; Kearns-Jonker MK; Lam TT; Jackson JR; Morris RE; Starnes VA; Cramer DV
    Xenotransplantation; 2007 Mar; 14(2):135-44. PubMed ID: 17381688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of a primate model of renal transplantation in the development of new monoclonal antibodies.
    Shapiro ME; Reed MH; Strom TB; Carpenter CB; Milford EL; Kirkman RL
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):58-60. PubMed ID: 2816938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.
    Hausen B; Gummert J; Berry GJ; Christians U; Serkova N; Ikonen T; Hook L; Legay F; Schuler W; Schreier MH; Morris RE
    Transplantation; 2000 Feb; 69(4):488-96. PubMed ID: 10708100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At.
    Wesley JN; McGee EC; Garmestani K; Brechbiel MW; Yordanov AT; Wu C; Gansow OA; Eckelman WC; Bacher JD; Flynn M; Goldman CK; MacLin M; Schwartz UP; Jackson-White T; Phillip CM; Decker J; Waldmann TA
    Nucl Med Biol; 2004 Apr; 31(3):357-64. PubMed ID: 15028248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversibility of cardiac xenograft rejection in primates.
    McManus RP; Kinney T; Komorowski R; Hunter J
    J Heart Lung Transplant; 1991; 10(4):567-76. PubMed ID: 1911800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1992 Stohlman Memorial Lecture: targeting the IL-2 receptor.
    Waldmann TA
    Leukemia; 1993 Aug; 7 Suppl 2():S151-6. PubMed ID: 8361223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA; Schmidberger H; Buchsbaum DJ; Everson P; Snover DC; Blazar BR
    Cancer Res; 1991 Apr; 51(7):1891-7. PubMed ID: 2004372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of IL 2R+ T cells and macrophages within rejecting rat cardiac allografts, and comparison of the effects of treatment with anti-IL 2R monoclonal antibody or cyclosporin.
    Hancock WW; Lord RH; Colby AJ; Diamantstein T; Rickles FR; Dijkstra C; Hogg N; Tilney NL
    J Immunol; 1987 Jan; 138(1):164-70. PubMed ID: 3097143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.